Since most symptomatic patients are tested for NF1 mutations before they visit a breast cancer clinic, these patients are not tested for mutations in BRCA1/2 genes for their breast disease, a requisite for enrollment in the current study. The gene discussed is NF1; the disease is breast carcinoma.